Earnings ·
Vaxart reports Q3 revenue of $10.6M and a net loss of $17.7M
VXRTVaxart, Inc.
Vaxart reported third-quarter 2026 revenue of $10.6 million, down from $72.4 million in the prior-year period, driven by reduced BARDA contract activity. The company posted a net loss of $17.7 million, or ($0.07) per share, compared to an $8.1 million loss previously. Cash and short-term investments stood at $65.5 million as of September 30, with management anticipating a cash runway into the second quarter of 2027. The firm expects to release topline efficacy data from its Phase 2b COVID-19 trial by mid-year 2027 and announced a new European patent for its norovirus vaccine candidate. Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet.